On April 22, 2022 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close (Press release, Lantern Pharma, APR 22, 2022, View Source [SID1234612841]). The company will host a conference call and webcast in a webinar format at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Tuesday, May 3, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management intends to discuss the operating and financial results for the first quarter ended March 31, 2022 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.

To register for the webinar, please sign up here: View Source

A replay of the webinar will be available on the investor relations section of the Company’s website: ir.lanternpharma.com.